[Immunotherapy of multiple recurring warts. II. Reassessment of the use of squaric acid dibutylester (SADBE) (author's transl)].
The treatment of recalcitrant multiple verrucae by sensitization to DNCB has been successfully used as shown in a previous study. Owing to the mutagenic effect of DNCB in Ames test, we tried a new non-mutagenic compound, SADBE to treat patients with multiple recurring warts. The study comprised 18 patients whose informed consent was obtained. They were sensitized to SADBE with a 2 p. 100 solution applied once and then treated with a 0.1 p. 100 solution weekly. The solution was applied by means of a swab on the warts. The concentration was adjusted to the patient's reactivity in order to maintain a mild contact dermatitis. The duration of treatment ranged from 4 to 13 weeks. Our results showed tat complete resolution of warts occurred in only 2 out of 18 patients. Side effects were negligible. In conclusion, we do not support the use of SADBE for treating multiple recurring warts.
D000293:Adolescent; D000328:Adult; D002648:Child; D003503:Cyclobutanes / Q000008:administration & dosage*; D006801:Humans; D007167:Immunotherapy; D008875:Middle Aged; D012008:Recurrence; D014860:Warts / Q000628:therapy*
D003503:Cyclobutanes; C020637:squaric acid dibutyl ester
Traitement des verrues multiples et récidivantes par induction d'une hypersensibilité retardée. II. Etude critique de l'utilisation du dibutylester de l'acide squarique.